Sun Pharma Advanced Research Co Ltd

Sun Pharma Advanced Research Company Ltd share price slipped 1.02% to Rs 175.1 after the company's net profit registered a growth of 17.37% to Rs 24.39 crore, while revenue from operations nosedived 24.77% to Rs 30.03 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 4.75%. It has improved by 2.16% over last one week and gained upto 0.86% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has eased by 1.90% and 19.75% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 24.31 crore in Q3 FY26, tumbling by 67.92% year-on-year, and expanding by 17.61% quarter-on-quarter. EBITDA came in at Rs 69 crore, gaining 5.32% YoY and rallying 20.07% sequentially. Total expenses saw a slight increase of 2.26% to Rs 77.84 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 9.95 crore, surging by 29.90% YoY, while employee benefits expense was at Rs 29.33 crore, softening 0.95% YoY. For the TTM ended FY26, revenue from operations plunged by 45.45% to Rs 39.15 crore, while net profit witnessed a sharp fall of 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA tanked by 32811% to Rs 1587.81 crore, and PBT tumbled by 553.06% to Rs 1553.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd jumped 24.89% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.

Sun Pharma Advanced Research Company Ltd will hold a board meeting on Monday, November 02, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the National Stock Exchange of India Ltd and BSE Limited. The trading window for company shares has been closed for directors, key managerial personnel, designated employees, and connected persons from October 01, 2026, and will remain closed until 48 hours after the financial results are declared and submitted to the stock exchanges.

Sun Pharma Advanced Research Company Ltd. submitted a confirmation certificate to the National Stock Exchange of India Ltd. and BSE Limited for the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with MUFG Intime (India) Private Limited acting as the Registrar and Share Transfer Agent.

Sun Pharma Advanced Research Company Limited informed the National Stock Exchange of India Ltd. and BSE Limited that the trading window for dealing in the company’s shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half year ended September 30, 2026.

Sun Pharma Advanced Research Company Ltd share price softened by 2.03% to Rs 212.85 after the company's net profit witnessed a sharp fall of 101.18% to Rs 20.78 crore, while revenue from operations gained significantly 202.42% to Rs 39.92 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, rising 5.16%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has marginally improved by 2.28% and 27.61% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 20.67 crore in Q2 FY26, crashing by 60.10% year-on-year, and tumbling by 101.17% quarter-on-quarter. EBITDA came in at Rs 58 crore, declining 5.82% YoY and plunging by 103.26% sequentially. Total expenses marginally dropped 7.64% to Rs 76.12 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.66 crore, soaring by 48.45% YoY, while employee benefits expense was at Rs 29.61 crore, soaring 13.80% YoY. For the TTM ended FY26, revenue from operations sank 45.45% to Rs 39.15 crore, while net profit tumbled by 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA saw a sharp decline of 32811% to Rs 1587.81 crore, and PBT plunged by 553.06% to Rs 1553.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd rallied 45.64% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

Sun Pharma Advanced Research Company Ltd will hold a board meeting on August 10, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing with the National Stock Exchange of India Ltd and BSE Limited. The trading window for company shares has been closed for directors, key managerial personnel, designated employees, and connected persons since July 1, 2026, and will remain closed until 48 hours after the financial results are declared and submitted to the stock exchanges.

Sun Pharma Advanced Research Company announced that the 21th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

Sun Pharma Advanced Research Company has allotted 3,85,10,000 warrants to Shanghvi Finance at an issue price of Rs 155.80/- per warrant on preferential basis, out of which the Company has received an amount of Rs 149.99 crore which is equivalent to 25% of the warrant issue price. Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of Re 1/- of the Company in accordance with the provisions of SEBI ICDR Regulations.

Net profit of Sun Pharma Advanced Research Company reported to Rs 1761.34 crore in the quarter ended March 2026 as against net loss of Rs 59.77 crore during the previous quarter ended March 2025. Sales declined 51.45% to Rs 13.20 crore in the quarter ended March 2026 as against Rs 27.19 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 1553.20 crore in the year ended March 2026 as against net loss of Rs 342.51 crore during the previous year ended March 2025. Sales declined 45.45% to Rs 39.15 crore in the year ended March 2026 as against Rs 71.77 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales13.2027.19 -51 39.1571.77 -45 OPM %13433.33-195.59 -4083.68-450.24 - PBDT1763.36-57.72 LP 1575.58-330.39 LP PBT1760.96-60.67 LP 1565.37-342.78 LP NP1761.34-59.77 LP 1553.20-342.51 LP Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 18 May 2026.